Your browser doesn't support javascript.
loading
Expanding access to early phase trials: the CATCH-UP.2020 experience.
Baranda, Joaquina C; Diaz, Francisco J; Rubinstein, Larry; Shields, Anthony F; Dayyani, Farshid; Mehta, Amitkumar; Mehnert, Janice M; Trent, Jonathan; Mabaera, Rodwell; Mooney, Margaret; Moscow, Jeffrey A; Doroshow, James; Waters, Brittany; Ivy, Percy; Gore, Steven D; Thomas, Alexandra.
Affiliation
  • Baranda JC; Department of Medical Oncology, University of Kansas Cancer Center, Kansas City, KS, USA.
  • Diaz FJ; Department of Biostatistics & Data Science, The University of Kansas Medical Center, Kansas City, KS, USA.
  • Rubinstein L; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
  • Shields AF; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Dayyani F; Division of Hematology/Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center-University of California Irvine, Irvine, CA, USA.
  • Mehta A; Division of Hematology and Oncology, Department of Internal Medicine, O'Neal Comprehensive Cancer Center-University of Alabama at Birmingham, Birmingham, AL, USA.
  • Mehnert JM; Department of Internal Medicine, Perlmutter Cancer Center of NYU Langone, NYU Grossman School of Medicine, New York, NY, USA.
  • Trent J; Department of Internal Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA.
  • Mabaera R; Section of Medical Oncology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Mooney M; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
  • Moscow JA; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
  • Doroshow J; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
  • Waters B; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
  • Ivy P; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
  • Gore SD; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA.
  • Thomas A; Department of Internal Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
JNCI Cancer Spectr ; 7(1)2023 01 03.
Article in En | MEDLINE | ID: mdl-36525371
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / Neoplasms Limits: Humans Language: En Journal: JNCI Cancer Spectr Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / Neoplasms Limits: Humans Language: En Journal: JNCI Cancer Spectr Year: 2023 Document type: Article Affiliation country: Country of publication: